

## Highlights of This Issue 1643

### SPECIAL FEATURES

#### CCR Translations

- 1645 | **A New Mechanism for Blocking Myeloid-Derived Suppressor Cells by CpG**  
Melissa G. Lechner and Alan L. Epstein  
*See article p. 1765*

#### CCR New Strategies

- 1649 | **New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway**  
Gerhardt Attard, Juliet Richards, and Johann S. de Bono

#### Molecular Pathways

- 1658 | **Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease**  
Adina Vultur, Jessie Villanueva, and Meenhard Herlyn

#### Special Report

- 1664 | **White Paper on Adoptive Cell Therapy for Cancer with Tumor-Infiltrating Lymphocytes: A Report of the CTEP Subcommittee on Adoptive Cell Therapy**  
Jeffrey Weber, Michael Atkins, Patrick Hwu, Laszlo Radvanyi, Mario Sznol, and Cassian Yee; on behalf of the Immunotherapy Task Force of the NCI Investigational Drug Steering Committee

#### Review

- 1674 | **Second-Generation Tyrosine Kinase Inhibitors: The Future of Frontline CML Therapy**  
Hagop M. Kantarjian, Michele Baccarani, Elias Jabbour, Giuseppe Saglio, and Jorge E. Cortes

## HUMAN CANCER BIOLOGY

- 1684 | **Large-Scale Analysis of *KIT* Aberrations in Chinese Patients with Melanoma**  
Yan Kong, Lu Si, Yanyan Zhu, Xiaowei Xu, Christopher L. Corless, Keith T. Flaherty, Li Li, Haifu Li, Xinan Sheng, Chuanliang Cui, Zhihong Chi, Siming Li, Mei Han, Lili Mao, Aiping Lu, and Jun Guo
- 1692 | **The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells**  
Lucía López-Corral, Norma C. Gutiérrez, María Belén Vidriales, María Victoria Mateos, Ana Rasillo, Ramón García-Sanz, Bruno Paiva, and Jesús F. San Miguel
- 1701 | **Analysis of the Oxidative Damage Repair Genes *NUDT1*, *OGG1*, and *MUTYH* in Patients from Mismatch Repair Proficient HNPCC Families (MSS-HNPCC)**  
Pilar Garre, Verónica Briceño, Rosa M. Xicola, Brian J. Doyle, Miguel de la Hoya, Julián Sanz, Patricia Llovet, Paula Pescador, Javier Puente, Eduardo Díaz-Rubio, Xavier Llor, and Trinidad Caldés
- 1713 | **Functional Roles of *Src* and *Fgr* in Ovarian Carcinoma**  
Hye-Sun Kim, Hee Dong Han, Guillermo N. Armaiz-Pena, Rebecca L. Stone, Eun Ji Nam, Jeong-Won Lee, Mian M. K. Shahzad, Alpa M. Nick, Sun Joo Lee, Ju-Won Roh, Masato Nishimura, Lingegowda S. Mangala, Justin Bottsford-Miller, Gary E. Gallick, Gabriel Lopez-Berestein, and Anil K. Sood
- 1722 | **Analysis of MiR-195 and MiR-497 Expression, Regulation and Role in Breast Cancer**  
Dan Li, Yulan Zhao, Changxing Liu, Xiaona Chen, Yanting Qi, Yue Jiang, Chao Zou, Xiaolong Zhang, Shunying Liu, Xuejing Wang, Dan Zhao, Qiang Sun, Zhenbing Zeng, Andreas Dress, Marie C. Lin, Hsiang-Fu Kung, Hallgeir Rui, Ling-Zhi Liu, Feng Mao, Bing-Hua Jiang, and Lihui Lai

1731 **Copy-Neutral Loss of Heterozygosity at the p53 Locus in Carcinogenesis of Esophageal Squamous Cell Carcinomas Associated with p53 Mutations**

Hiroshi Saeki, Hiroyuki Kitao, Keiji Yoshinaga, Tomonori Nakanoko, Nobuhide Kubo, Yoshihiro Kakeji, Masaru Morita, and Yoshihiko Maehara

1741 **Brain-Derived Neurotrophic Factor and Neurotrophin-4/5 Are Expressed in Breast Cancer and Can Be Targeted to Inhibit Tumor Cell Survival**

Elsa Vanhecke, Eric Adriaenssens, Stéphanie Verbeke, Samuel Meignan, Emmanuelle Germain, Nathalie Bertheaux, Victor Nurcombe, Xuefen Le Bourhis, and Hubert Hondermarck

## CANCER THERAPY: PRECLINICAL

1753 **Carfilzomib-Dependent Selective Inhibition of the Chymotrypsin-like Activity of the Proteasome Leads to Antitumor Activity in Waldenstrom's Macroglobulinemia**

Antonio Sacco, Monette Aujay, Brittany Morgan, Abdel Kareem Azab, Patricia Maiso, Yang Liu, Yong Zhang, Fedaa Azab, Hai T. Ngo, Ghayas C. Issa, Phong Quang, Aldo M. Roccaro, and Irene M. Ghobrial

1765 **CpG Blocks Immunosuppression by Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice**

Christine Zoglmeier, Helen Bauer, Daniel Nörenberg, Georg Wedekind, Philipp Bittner, Nadja Sandholzer, Moritz Rapp, David Anz, Stefan Endres, and Carole Bourquin

*See commentary p. 1645*

1776 **Differential Response of Human and Mouse Dendritic Cells to VEGF Determines Interspecies Discrepancies in Tumor-Mediated Th1/Th2 Polarity Shift**

Matthew S. Block, Wendy K. Nevala, Alexey A. Leontovich, and Svetomir N. Markovic

1784 **Pancreatic Tumor Suppression by Benzyl Isothiocyanate Is Associated with Inhibition of PI3K/AKT/FOXO Pathway**

Srinivas Reddy Boreddy, Kartick C. Pramanik, and Sanjay K. Srivastava

1796 **Nelfinavir Induces Liposarcoma Apoptosis through Inhibition of Regulated Intramembrane Proteolysis of SREBP-1 and ATF6**

Min Guan, Kristen Fousek, Chunling Jiang, Song Guo, Tim Synold, Bixin Xi, Chu-Chih Shih, and Warren A. Chow

1807 **Riluzole Enhances Ionizing Radiation-Induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 *In Vitro* and *In Vivo***

Atif J. Khan, Brian Wall, Stuti Ahlawat, Camille Green, Devora Schiff, Janice M. Mehnert, James S. Goydos, Suzie Chen, and Bruce G. Haffty

1815 **Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation *In Vivo* and *In Vitro***

Daisuke Sano, Fumihiko Matsumoto, David R. Valdecanas, Mei Zhao, David P. Molkentine, Yoko Takahashi, Ehab Y. Hanna, Vali Papadimitrakopoulou, John Heymach, Luka Milas, and Jeffrey N. Myers

1828 **Preclinical Evaluation of Telomerase-Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas**

Tsuyoshi Sasaki, Hiroshi Tazawa, Jo Hasei, Toshiyuki Kunisada, Aki Yoshida, Yuuri Hashimoto, Shuya Yano, Ryosuke Yoshida, Futoshi Uno, Shunsuke Kagawa, Yuki Morimoto, Yasuo Urata, Toshifumi Ozaki, and Toshiyoshi Fujiwara

1839 **Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NF-κB Pathway in Human Non-Small Cell Lung Cancer**

Libing Song, Huaping Xiong, Jun Li, Wenting Liao, Lan Wang, Jueheng Wu, and Mengfeng Li

## IMAGING, DIAGNOSIS, PROGNOSIS

1850 **Gene Expression Signature-Based Prognostic Risk Score in Gastric Cancer**

Jae Yong Cho, Jae Yun Lim, Jae Ho Cheong, Yun-Yong Park, Se-Lyun Yoon, Soo Mi Kim, Sang-Bae Kim, Hoguen Kim, Soon Won Hong, Young Nyun Park, Sung Hoon Noh, Eun Sung Park, In-Sun Chu, Waun Ki Hong, Jaffer A. Ajani, and Ju-Seog Lee

1858 **Intraoperative qRT-PCR for Detection of Lymph Node Metastasis in Head and Neck Cancer**

Robert L. Ferris, Liqiang Xi, Raja R. Seethala, Jon Chan, Shaun Desai, Benjamin Hoch, William Gooding, and Tony E. Godfrey

- 1867 **Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women**  
Rong Hu, Shaheenah Dawood, Michelle D. Holmes, Laura C. Collins, Stuart J. Schnitt, Kimberley Cole, Jonathan D. Marotti, Susan E. Hankinson, Graham A. Colditz, and Rulla M. Tamimi
- 1875 **The Association of MicroRNA Expression with Prognosis and Progression in Early-Stage, Non-Small Cell Lung Adenocarcinoma: A Retrospective Analysis of Three Cohorts**  
Motonobu Saito, Aaron J. Schetter, Steen Mollerup, Takashi Kohno, Vidar Skaug, Elise D. Bowman, Ewy A. Mathé, Seiichi Takenoshita, Jun Yokota, Aage Haugen, and Curtis C. Harris
- 1883 **Rapid Diagnosis of Medulloblastoma Molecular Subgroups**  
Ed C. Schwalbe, Janet C. Lindsey, Debbie Straughton, Twala L. Hogg, Michael Cole, Hisham Megahed, Sarra L. Ryan, Meryl E. Lusher, Michael D. Taylor, Richard J. Gilbertson, David W. Ellison, Simon Bailey, and Steven C. Clifford
- 1895 **Reduced p21<sup>WAF1/CIP1</sup> via Alteration of p53-DDX3 Pathway Is Associated with Poor Relapse-Free Survival in Early-Stage Human Papillomavirus-Associated Lung Cancer**  
De-Wei Wu, Wen-Shan Liu, John Wang, Chih-Yi Chen, Ya-Wen Cheng, and Huei Lee
- 1906 **Prognostic Utility of Anti-EBV Antibody Testing for Defining NPC Risk among Individuals from High-Risk NPC Families**  
Kelly J. Yu, Wan-Lun Hsu, Ruth M. Pfeiffer, Chun-Ju Chiang, Cheng-Ping Wang, Pei-Jen Lou, Yu-Juen Cheng, Patti Gravitt, Scott R. Diehl, Alisa M. Goldstein, Chien-Jen Chen, and Allan Hildesheim
- 1915 **Identification of a Soluble Form of B7-H1 that Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma**  
Xavier Frigola, Brant A. Inman, Christine M. Lohse, Christopher J. Krco, John C. Cheville, R. Houston Thompson, Bradley Leibovich, Michael L. Blute, Haidong Dong, and Eugene D. Kwon
- 1924 **Array-Based Comparative Genomic Hybridization Identifies CDK4 and FOXM1 Alterations as Independent Predictors of Survival in Malignant Peripheral Nerve Sheath Tumor**  
Jinsheng Yu, Hrishikesh Deshmukh, Jacqueline E. Payton, Christopher Dunham, Bernd W. Scheithauer, Tarik Tihan, Richard A. Prayson, Abhijit Guha, Julia A. Bridge, Rosalie E. Ferner, Guy M. Lindberg, Rebecca J. Gutmann, Ryan J. Emnett, Lorena Salavaggione, David H. Gutmann, Rakesh Nagarajan, Mark A. Watson, and Arie Perry
- CANCER THERAPY: CLINICAL**
- 1935 **Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma**  
Annunziata De Luisi, Arianna Ferrucci, Addolorata M.L. Coluccia, Roberto Ria, Michele Moschetta, Emanuela de Luca, Luisa Pieroni, Michele Maffia, Andrea Urbani, Giulia Di Pietro, Attilio Guarini, Girolamo Ranieri, Paolo Ditunno, Simona Berardi, Antonella Caivano, Antonio Basile, Nicola Cascavilla, Silvana Capalbo, Giovanni Quarta, Franco Dammacco, Domenico Ribatti, and Angelo Vacca
- 1947 **Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP-Sponsored Clinical Trials**  
Steven K. Cheng, Mary S. Dietrich, and David M. Dilts
- 1956 **Two Drug Interaction Studies of Sirolimus in Combination with Sorafenib or Sunitinib in Patients with Advanced Malignancies**  
Tara C. Gangadhar, Ezra E.W. Cohen, Kehua Wu, Linda Janisch, David Geary, Masha Kocherginsky, Larry K. House, Jackie Ramirez, Samir D. Undevia, Michael L. Maitland, Gini F. Fleming, and Mark J. Ratain
- 1964 **Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors**  
Vanessa Gregorc, Filippo G. De Braud, Tommaso M. De Pas, Roberto Scalamogna, Giovanni Citterio, Alessandra Milani, Sabrina Boselli, Chiara Catania, Giovanni Donadoni, Gilda Rossoni, Domenico Ghio, Gianluca Spitaleri, Cristina Ammannati, Scialini Colombi, Federico Caligaris-Cappio, Antonio Lambiase, and Claudio Bordignon

- 1973 **Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma**  
Joong-Won Park, Richard S. Finn, Jun Suk Kim, Mark Karwal, Ruby K. Li, Fuad Ismail, Melanie Thomas, Rosemarie Harris, Christine Baudelet, Ian Walters, and Jean-Luc Raoul
- 1984 **Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation *In Vitro*, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells *In Vivo***  
Emanuela Romano, Marco Rossi, Gudrun Ratzinger, Maria-Angeles de Cos, David J. Chung, Katherine S. Panageas, Jedd D. Wolchock, Alan N. Houghton, Paul B. Chapman, Glenn Heller, Jianda Yuan, and James W. Young
- 1998 **A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma**  
Sarah M. Rudman, Michael B. Jameson, Mark J. McKeage, Philip Savage, Duncan I. Jodrell, Mark Harries, Gary Acton, Fredrik Erlandsson, and James F. Spicer
- 2024 **A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance**  
Todd W. Miller, Justin M. Balko, Zara Ghazoui, Anita Dunbier, Helen Anderson, Mitch Dowsett, Ana M. González-Angulo, Gordon B. Mills, William R. Miller, Huiyun Wu, Yu Shyr, and Carlos L. Arteaga
- 2035 **DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy**  
Benjamin J. Moeller, John S. Yordy, Michelle D. Williams, Uma Giri, Uma Raju, David P. Molkenkine, Lauren A. Byers, John V. Heymach, Michael D. Story, J. Jack Lee, Erich M. Sturgis, Randal S. Weber, Adam S. Garden, K. Kian Ang, and David L. Schwartz
- 2044 **Identification of Soluble Candidate Biomarkers of Therapeutic Response to Sunitinib in Medullary Thyroid Carcinoma in Preclinical Models**  
Sophie Broutin, Nabahet Ameer, Ludovic Lacroix, Thomas Robert, Benoit Petit, Nassima Oumata, Monique Talbot, Bernard Caillou, Martin Schlumberger, Corinne Dupuy, and Jean-Michel Bidart
- 2055 **HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care**  
Alessandra Fabi, Anna Di Benedetto, Giulio Metro, Letizia Perracchio, Cecilia Nisticò, Franco Di Filippo, Cristiana Ercolani, Gianluigi Ferretti, Elisa Melucci, Simonetta Buglioni, Isabella Sperduti, Paola Papaldo, Francesco Cognetti, and Marcella Mottolese
- 2006 **A Polymorphism in the *Cytidine Deaminase* Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome**  
Daniela Caronia, Miguel Martin, Javier Sastre, Julio de la Torre, José Angel García-Sáenz, Maria R. Alonso, Leticia T. Moreno, Guillermo Pita, Eduardo Díaz-Rubio, Javier Benítez, and Anna González-Neira
- 2014 **The A/G Allele of Rs16906252 Predicts for MGMT Methylation and Is Selectively Silenced in Premalignant Lesions from Smokers and in Lung Adenocarcinomas**  
Shuguang Leng, Amanda M. Bernauer, Chibo Hong, Kieu C. Do, Christin M. Yingling, Kristina G. Flores, Mathewos Tessema, Carmen S. Tellez, Randall P. Willink, Elizabeth A. Burki, Maria A. Picchi, Christine A. Stidley, Michael D. Prados, Joseph F. Costello, Frank D. Gilliland, Richard E. Crowell, and Steven A. Belinsky
- 2065 **Intraarterial Treatment of GEP NET: <sup>68</sup>Ga-DOTATOC SUV Cannot Predict <sup>90</sup>Y-DOTATOC Uptake**  
Claudia Broggitter, Diana Faulhaber, and Jörg Kotzerke

## PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

## LETTER TO THE EDITOR

---

**CORRECTIONS**

2068

**Correction: Microenvironmental Regulation of Glioblastoma Radioresponse**


2066

**Correction: Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models**

---

**ABOUT THE COVER**

AKT phosphorylates FOXO, which causes shuttling of FOXO1 from nucleus to cytoplasm. Cytoplasmic localization of FOXO1 protects the cells from FOXO/Bim-induced apoptosis. Treatment of BxPC-3 cells with benzyl isothiocyanate (BITC) induces nuclear retention of FOXO1 resulting in the transcriptional upregulation of Bim, leading to apoptosis in pancreatic cancer cells. BxPC-3 cells were treated with 10 $\mu$ mol/L BITC for 24 hours and immunostained with FOXO1 (red) and actin (green) antibodies overnight, followed by a 2-hour incubation with Alexa fluor 594 and Alexa fluor 488 antibodies, respectively. Cells were photographed under microscope (60x) after staining the nucleus with DAPI (blue). For further details, please see Boreddy and coworkers on page 1784 in this issue.



# Clinical Cancer Research

**17 (7)**

*Clin Cancer Res* 2011;17:1643-2068.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/17/7>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/17/7>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.